SynthesisFrontiers in oncology2026
Efficacy and safety of immunotherapy in head and neck tumors: a systematic review and meta-analysis of clinical outcomes and survival benefits.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The treatment of head and neck squamous cell carcinoma (HNSCC) poses significant difficulties because patients with advanced disease experience poor survival rates. The use of immune checkpoint inhibitors as therapy shows potential, yet researchers report inconsistent findings regarding their effectiveness and safety in clinical trials and real-world settings. Objective: The study aimed to assess the effectiveness and safety of immunotherapy for HNSCC, as well as treatment success by biomarker status, through a systematic review and meta-analysis of clinical and real-world evidence. Methodology: The researchers conducted a comprehensive systematic review and meta-analysis that included all available randomized controlled trials, phase II and III studies, retrospective cohort studies, and real-world evidence. The researchers applied a random-effects model analysis, using inverse-variance weighting and a Freeman-Tukey double arcsine transformation, to pool the data. The I² statistic served as the measure of heterogeneity, while publication bias was assessed using funnel plots and Egger's test. The GRADE methodology assessed the certainty of the evidence. Results: The analysis included 36 studies involving 8880 to 5930 patients, assessed across five main outcome categories. The clinical effectiveness assessment showed a combined rate of 0.16 (95% CI: 0.14-0.18), with considerable heterogeneity (I² = 81%). The effectiveness assessment showed a combined rate of 0.18 (95% CI: 0.16-0.19), which displayed evidence of publication bias. The combination therapies achieved an improvement rate of 0.18 (95% CI: 0.15-0.22), whereas the dual/targeted immunotherapy showed superior performance, with an improvement rate of 0.22 (95% CI: 0.19-0.24), based on highly reliable evidence. The PD-L1-based outcomes showed a pooled proportion of 0.17 (95% CI: 0.16-0.19) with moderate heterogeneity (I² = 66%). The majority of randomized controlled datasets showed no evidence of publication bias. Conclusion: Immunotherapy delivers moderate yet dependable medical results for HNSCC, with its greatest effectiveness achieved through dual- or targeted-treatment methods. The randomized research evidence shows strong treatment effects, whereas the actual treatment data reveal different results and suggest possible publication bias. The PD-L1 biomarker is a useful tool for predicting response, yet its performance is inconsistent across applications. The use of immunotherapy represents a major development in HNSCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.